Twenty-seven patients with serious gram-negative infections were treated with ticarcillin in an average daily dosage of 237 mg/kg (range, 174 to 307 mg/ kg). Ticarcillin was bactericidal for all infecting organisms in concentrations ranging from 31.2 to 125 ,ug/ml. Five of 8 patients (62%) with overwhelming Pseudomonas pneumonia were cured or improved, and 9 of 12 (75%) were cured of pneumonia caused by other gram-negative organisms. Of six extrapulmonary infections caused by Pseudomonas, five (83%) were cured or improved. In seven cases, the infecting organism reisolated during therapy was more resistant to ticarcillin than the primary isolate. The serum half-life of ticarcillin in three patients with renal failure was 11.2 ± 1.0 h, and during hemodialysis it decreased to 6.3 ± 1.8 h. There were two episodes of superinfection with resistant organisms. Thirteen patients (48%) manifested eosinophilia, one of whom had severe urticaria. Prolongation of bleeding time was attributable to ticarcillin in two patients. Ticarcillin appears to be effectivefor therapy of serious gram-negative infections in dosages 30 to 50% less than those recommended for carbenicillin.
Although gentamicin and carbenicillin have significantly improved the treatment of serious infections caused by Pseudomonas aeruginosa, the reported cure rates are not high, ranging from approximately 70%o in acute bacteremia to 15% in cases of pneumonia (2, 17) . A significant advance in the search for penicillins with improved activity against P. aeruginosa has been the synthesis of ticarcillin (a-carboxy-3-thienylmethylpenicillin) by the Beecham Research Laboratories (23) . The acyl side chain of both ticarcillin and carbenicillin contains an acarboxy group that appears to confer antimicrobial activity against P. aeruginosa. Ticarcillin, however, has a 3-thienyl group in place of the phenyl group of carbenicillin. Other properties, including salt content (4.7 meq/g), are almost identical (12) .
The in vitro activity of ticarcillin is two-to threefold greater than carbenicillin against Pseudomonas (13) . It is very active against Neisseria meningiditis and Haemophilus influenzae (20) and is more resistant than ampicillin to the action of staphylococcal penicillinase (23) . Furthermore, ticarcillin is bacteriostatic to many strains of Enterobacter, Serratia, and indole-positive species of Proteus at concentrations easily achieved in viyo (23) . The activity against Escherichia coli and Proteus mirabilis is equivalent to that of ampicillin but, like carbenicillin, ticarcillin is less active than ampicillin against Streptococci and penicillinsensitive Staphylococci (23) . Most strains of Enterococcus and Klebsiella are resistant (2) .
It is the purpose of this communication to report the results of studies on the clinical pharmacology and efficacy of ticarcillin when used as the sole antibiotic for treatment of 27 patients seriously ill with gram-negative infections.
MATERIAL AND METHODS
In vitro studies. The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of ticarcillin for 212 clinical isolates were determined in Mueller-Hinton broth (BBL, Baltimore, Md.) by using the microtiter method of Harwick et al. (7) . Ticarcillin powder for assay was kindly supplied by Beecham Pharmaceuticals, Bristol, Tenn., and tested in concentrations ranging from 1.95 to 1,000 itg/ml. Wells were inoculated with a 0.5 x 10-3 dilution of an overnight growth (approximately 105 organisms/ml). The concentration of ticarcillin in the first clear well after 18 h of aerobic growth was considered to be the MIC. Clear wells were subcultured using a 0.01-ml calibrated loop, and the first well from which no colonies grew was considered to be the MBC.
Assay of body fluids. The concentration of ticarcillin in serum and other body fluids was assayed by an agar overlay well diffusion technique. Eugonagar (BBL) was used as both the base (20 ml) and seed (15 ml) agar in 150-mm plastic petri dishes. The assay organism was P. aeruginosa (NCTCC 10490), a strain susceptible to ticarcillin TICARCILLIN IN GRAM-NEGATIVE INFECTIONS but not its decarboxylation product (about 1%, wt/wt) formed during manufacture (1, 23) . The assay organism was grown overnight in brain heart infusion (BBL), diluted to give 70 to 75% light transmission at 650 nm, and incorporated into seed agar at a concentration of 0.6%, vol/vol. A stock solution of ticarcillin containing 8,000 ug/ml was prepared in 0.2 M phosphate buffer (pH 7.0). From this, working standards were made up containing 200, 100, 50, 25, and 12.5 ,ug/ml. Standards diluted in human serum were used for the assay of ticarcillin in pleural fluid, bile, and serum. Standards in buffer were used for assay of cerebrospinal fluid or urine. Standards were stored at -70 C for no more than 5 days. Each standard or unknown was assayed in quadruplicate, and data from the assay of standards were used to calculate a reference curve by means of the linear regression method of least squares (22) . Unknown samples found to contain greater than 200 ,ug/ml were diluted and reassayed. The error of assay was ± 10%o at the 95% confidence level. The half-life (t12) of ticarcillin was calculated by the method of Kunin and Finland (10) .
Patient selection and dosage schedule. Twentyseven inpatients with serious gram-negative infections were studied, all of whom had given informed consent for treatment, according to a protocol approved by the University of Kentucky Human Investigations and Studies Committee. Fourteen patients had received no prior antimicrobial therapy, and 13 had not responded to other antibiotics. Ticarcillin was the sole antibiotic administered to 26 of the 27 patients; 1 also received vancomycin. Gentamicin was added to the treatment regimen of three patients after 1 week because of poor response to ticarcillin or superinfection. From 20 patients with pneumonia, specimens for culture were obtained by transtracheal aspiration (8 patients), aspiration of tracheostomies (8 patients), and in 4 cases by collection of purulent sputum or empyema fluid. Serial blood samples for assay and calculation of the tl, of ticarcillin in serum were obtained from two patients under treatment for infection and from five noninfected volunteers with end-stage renal failure requiring chronic dialysis.
The average daily dosage of ticarcillin given to patients with normal renal function was 237 mg/kg (range, 174 to 307 mg/kg), divided into six equal doses. A subgroup of 14 patients with Pseudomonas infections received an average daily dosage of 260 mg/kg (range, 236 to 307 mg/kg). One of these was treated with 400 mg/kg per day after responding poorly to 240 mg/kg per day given for one week. Of the patients in renal failure, one received 75 mg/kg per day, divided into three equal doses; four others were treated with 40 mg/kg daily. Ticarcillin was administered to 26 of the 27 patients by an intravenous infusion over 10 min.
The following laboratory studies were obtained prior to therapy and at 1-week intervals thereafter: complete blood count, serum glutamic oxaloacetic transaminase, alkaline phosphatase, blood urea nitrogen, creatinine, calcium, phosphorus, potassium, uric acid, creatine phosphokinase, lactic dehydrogenase, and urinalysis. Skin bleeding time was measured by the standardized template Ivy bleeding time technique (15) . Skin bleeding time was considered to be abnormal if greater than 10 min.
Definition of therapeutic results. Therapeutic results were defined as follows: "cure," eradication of the pathogen, disappearance of clinical signs and symptoms, and normalization of laboratory findings; "improvement," amelioration of clinical signs and symptoms without resolution of infection; "relapse," improvement as defined, followed by clinical deterioration and reisolation of the initial pathogen; "superinfection," a second infection caused by a different organism during therapy; "failure," no clinical improvement with persistence of infecting organism.
RESULTS
In vitro studies. The susceptibility of P. aeruginosa to ticarcillin in vitro is presented in Table 1 . Of 100 strains, 69%o were inhibited by a concentration of 31.2 ,g/ml, and 97% were inhibited by 62.5 ug/ml. The MBC for 94% of the strains was equal to or one dilution lower than the MIC. Ticarcillin was bactericidal for all strains at a concentration of 125 ,ug/ml or less. The MBC for 14 additional strains isolated from patients treated with ticarcillin ranged from 31.2 to 125 gg/ml.
Clinical studies-pulmonary infections. The salient clinical features of 20 patients with severe pneumonia are presented in Table 2 . In eight patients, all with serious underlying disease, the pneumonia was caused by Pseudomonas and, in six of these, three or more lobes were consolidated by the infection. Three of the eight patients responded well to therapy and resolved their pneumonia within 14 days. Patient no. 7 had received 30 g of carbenicillin per day; however, his blood cultures remained positive for Pseudomonas. Ticarcillin was instituted in a dosage of 18 g/day without significant improvement over a 4-day period, whereupon the dosage was increased to 400 mg/ kg per day (30 g/day). On this regimen, the serum level of ticarcillin measured 1 h after a dose of 5 g was 192 jig/ml. At trough antibiotic levels, his serum was bactericidal for the infecting organism in a dilution of 1:2. The response to increased dosage was dramatic, with marked clinical improvement after 24 h and recovery within 14 days. During the early-treatment phase, this patient received gentamicin. However, therapy was discontinued after the MIC for gentamicin was found to be 31.2,g/ml.
Two of the eight patients with Pseudomonas pneumonia clearly improved. One (no. 14) regained sufficient pulmonary function to permit discontinuation of mechanical ventilation, de- spite the presence of residual infection. The second patient (no. 2) was improving on ticarcillin therapy; however, the onset of severe urticaria precipitated a change to gentamicin for the completion of treatment.
The three patients (no. 5, 6, 8) who relapsed or failed to respond were critically ill with pancreatitis, massive abdominal gunshot wounds, and hepatorenal failure, respectively. Pseudomonas was repeatedly isolated from patient no.
5, and during ticarcillin therapy there was superinfection with K. pneumoniae that proved fatal, although gentamicin (4 mg/kg per day) was added to the therapeutic regimen. Patient no. 8 epitomizes the difficulties involved in the attempt to maintain adequate, but not toxic, serum levels of ticarcillin during the treatment of patients with hepatorenal failure. After isolation of P. aeruginosa from the tracheostomy, ticarcillin was initiated in a dosage of 2 g/day. Under this regimen, the serum levels of ticarcillin ranged from 76 to 104 ,tg/ml, and there was gradual clearing of the pneumonia. On day 14, the dosage was increased to 4 g/day after reisolation of Pseudomonas susceptible to 125 ,ug of ticarcillin per ml. Thereafter, serum levels ranged from 166 to 194 ,ug/ml. Unfortunately, the patient developed Pseudomonas meningitis on day 17. The ticarcillin level in the spinal fluid withdrawn at the first lumbar puncture was 112 ,g/ml; the simultaneous serum level was 178 ,ug/ml. Ticarcillin dosage was again increased to 6 g/day and gentamicin, to which the organism was susceptible (MBC, 1.56 ug/ml), was administered intrathecally and intravenously. Subsequent serum levels of ticarcillin ranged between 172 and 314 ,ug/ml. The cerebrospinal fluid could not be sterilized, and the patient expired on day 36 of ticarcillin therapy. The MIC of ticarcillin for the Pseudomonas isolated from spinal fluid 3 days prior to death was 1,000 ,ug/ml.
Patients with pneumonia caused by pathogens highly susceptible to ticarcillin, such as E. coli, H. influenzae, and P. mirabilis, responded well to therapy. Similarly, one patient (no. 13) with pneumonia caused by Bacteriodes melaninogenicus responded promptly. However, another patient (no. 14) with presumed anaerobic pneumonia (gram-negative organism lost in anaerobic sub-culture) did not respond to 14 days of ticarcillin therapy, although a lobe cavitated and an empyema was drained. It is worth noting that this patient was granulocytopenic secondary to Felty's syndrome. Of three nosocomial pneumonias caused by species of Serratia or Enterobacter, one was cured (no. 9), and one improved (no. 11) but succumbed to hepatic failure. The third (no. 10) became afebrile and unproductive of sputum but failed to resolve his pneumonia over a 2-week period prior to nursing home transfer.
Extrapulmonary infections. The clinical features of seven patients with extrapulmonary infections are summarized in Table 3 . Ticarcillin was rapidly effective in terminating Pseudomonas sepsis in a patient with third-degree burns (no. 21). He became afebrile within 48 h, and blood cultures drawn 4 days after initiation of ticarcillin therapy were negative. Three patients (no. 22, 23, 24) with extensive soft-tissue infections caused by Pseudomonas responded well to ticarcillin and surgical drainage. Patient no. 23 with bilateral costochondritis had responded well to ticarcillin but discharged himself against medical advice on day 15 of therapy. The Pseudomonas isolated before treatment was susceptible to 62.5 ,ug of ticarcillin per ml, whereas 250 A&g/ml was required to inhibit growth of a strain isolated prior to discharge. One month later the patient returned for surgical biopsy from which was isolated a strain ofPseudononas susceptible to 31
.tg/ml. Ticarcillin was reinstituted with eradication of the infection after 28 days of therapy.
All three urinary tract infections treated with ticarcillin (no. 25, 26, 27) were associated with structural abnormalities of the genitourinary tract. Although the blood leukocyte count of patient no. 25 In a few instances, it was possible to measure ticarcillin levels in other body fluids. As mentioned previously, ticarcillin was present in the cerebrospinal fluid of patient no. 8 in a concentration of 112 jig/ml (serum level, 178 ,ig/ml). Fifteen days later, the cerebrospinal fluid level was 172 ,ug/ml and the serum level was 308 jig/ml. The level in bile assayed on one occasion was 164 ,ig/ml, and the simultaneous serum level was 178 ,ig/ml. Ticarcillin was measured in pleural fluid from four patients with thoracostomy tubes. In three fluids, the levels were 63, 49, and 19 ,ug/ml, and the serum concentrations were 95, 164, and 55 ,ug/ml, respectively. No measurable ticarcillin was found in the thoracostomy drainage of one patient (no. 14), although the serum level was 89 ,ig/ml. Ticarcillin was also measured in the spontaneously voided urine of three patients with end-stage renal failure (CCr < 3.7 ml/min) whose daily urinary output was 500 to 1,200 ml/ day. The mean level was 202 + 15 jug/ml.
The mean serum ti of ticarcillin in three patients with renal failure requiring hemodialysis was 11.2 1.0 h. During hemodialysis with a Travenol Ultra-Flo II coil, the ti decreased to 6.3 + 1.8 h. In another patient undergoing peritoneal dialysis, the serum ti decreased to 7.8 h.
Complications of ticarcillin therapy. There were two episodes of superinfection with a ticarcillin-resistant organism, one in which a draining empyema cavity became superinfected with K. pneumoniae on day 12 of treatment (patient no. 14). Ticarcillin was replaced by cefazolin and gentamicin, which resolved the superinfection within 12 days. Patient no. 5 also became superinfected with K. pneumoniae. After day 5 of therapy, her tracheostomy secretions yielded an abundant growth of this organism in addition to Pseudomonas. Gentamicin (4.5 mg/kg per day) was added to the therapeutic regimen, with eradication of the Klebsiella 13 days later. Three patients with indwelling urinary catheters experienced significant (105 colonies/ml) candiduria during ticarcillin therapy. Upon completion of ticarcillin therapy, candiduria ceased in two of the three patients. Candida persisted in the urine of the third patient until the time of her death 7 days after the termination of therapy. One patient recovered from Candida stomatitis while receiving ticarcillin, and another required topical antifungal therapy for monilial dermatitis.
The clinical and biochemical dysfunctions associated with ticarcillin therapy are summarized in Table 6 . Thirteen of 27 patients (48.1%) manifested eosinophilia ranging from 3 to 15% of the leukocyte differential count. Of these, one developed severe urticaria, requiring cessation of therapy. The skin bleeding time was prolonged in six patients during ticarcillin therapy. Two of these hemorrhaged from the upper gastrointestinal tract. However, both had hemorrhagic gastritis and marked depletion of clotting factors secondary to severe liver (25) . Thus, of the 15 patients with Pseudomonas pneumonia reported to date, ticarcillin has cured 6 (40%), improved 3 (20%), and failed in 6 (40%). Although this data is too fragmentary to permit a definitive conclusion, experience to date suggests that ticarcillin in dosages of 15 to 21 g/day may not represent a significant advance over carbenicillin for treatment of Pseudomonas pneumonia (8) . Indeed, optimism is not fostered by the fact that moderately resistant strains were isolated during therapy from four of our eight patients with Pseudomonas pneumonia.
The mechanism of this resistance is poorly understood, despite the fact that similar emergence of microbial resistance during carbenicillin therapy has been recognized for several years (8, 14) . Although the seven resistant organisms isolated from patients were not tested for episomally mediated (-lactamase production, it seems unlikely that resistance was mediated by this mechanism since resistant strains isolated from clinical material do not appear to inactivate ticarcillin (16) . In vitro studies have demonstrated that serial passage ofP. aeruginosa in increasing concentrations of carbenicillin results in the growth of variants resistant to this antibiotic (4, 11) . Similar in vitro studies with ticarcillin are not yet reported. Nevertheless, it appears likely that the increase in resistance to ticarcillin that we have observed in vivo occurred in stepwise fashion and did not arise from de novo mutation to ,3-lactamase production by the infecting recommendation is likely to be made for combination therapy with ticarcillin since synergism between this antibiotic and gentamicin has been demonstrated in vitro (16, 23) . However, the putative advantages of such a combination must be weighed against the risk of gentamicin nephrotoxictty and ototoxicity, as well as the probability that gentamicin will not delay the emergence of resistance to ticarcillin, as illustrated by patient no. 8 and by past experience with carbenicillin (21) . Furthermore, there is now strong evidence that both carbenicillin and ticarcillin significantly reduce the serum ti of gentamicin when given in high dosage to patients with renal failure ( 
